LORIOT , Marie-Anne

Last name: LORIOT

First name: Marie-Anne

April 2017 (v1)

Journal article

Metadata-only

Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing

Etienne-Grimaldi, Marie-Christine Le Guellec, Chantal Barin Boyer, Jean-Christophe

International audience

Uploaded on: December 4, 2022
April 2018 (v1)

Journal article

Metadata-only

Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx

Loriot, Marie-Anne Ciccolini, Joseph Thomas, Fabienne

Les fluoropyrimidines restent les molécules anticancéreuses les plus prescrites dans le traitement des tumeurs solides. Elles induisent des toxicités sévères chez 10–40 % des patients et des toxicités létales chez 0,2–0,8 % des patients. Une abondante littérature a établi le lien entre un déficit enzymatique en dihydropyrimidine déshydrogénase...

Uploaded on: December 4, 2022
September 2019 (v1)

Journal article

Metadata-only

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Loriot, Marie-Anne Masskouri, Fadil Carni, Paolo

Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of early severe toxicities induced by fluoropyrimidines (FP). The French Group of Clinical Oncopharmacology (GPCO)-Unicancer and the French Pharmacogenetics Network (RNPGx) initiated two surveys, one addressed to oncologists, the other to biologists, in order to evaluate routine...

Uploaded on: December 3, 2022

LORIOT , Marie-Anne

Recent uploads